The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma

Kamikawa Rintaro

Ikawa Kazuro

Morikawa Norifumi

Asaoku Hideki

Iwato Koji

Sasaki Ayako

Biological and Pharmaceutical Bulletin

Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response. The aim of this study was to characterize the pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, and to examine the relationship between pharmacokinetics and adverse events. On the first and second days, a 100 mg capsule was administered to 8 Japanese patients after breakfast and blood samples were obtained. The plasma concentrations were measured using HPLC and analyzed based on a one-compartment model. If intolerable adverse events were not observed for 14 d, the dose was increased to 200 mg. The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration–time curve from 0 to infinity (AUC0—∞), which were 45.3 l, 5.5 l/h and 21.7 μg·h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0—∞ than in Caucasian populations. This pharmacokinetic difference may explain the dose difference between Japan and other countries. Adverse events were associated with AUC0—∞, which was best correlated with plasma concentration at 12 h after administration. The 12-h time point was suggested to be a capable indicator for “safety-oriented” therapeutic drug monitoring of thalidomide.

thalidomide

pharmacokinetics

multiple myeloma

Medical sciences [ 490 ]

eng

The Pharmaceutical Society of Japan

© 2006 Pharmaceutical Society of Japan

[ISSN] 0918-6158

[ISSN] 1347-5215

[NCID] AA10885497

[DOI] 10.1248/bpb.29.2331

[DOI] https://doi.org/10.1248/bpb.29.2331